Quantamental Technologies LLC acquired a new position in shares of Cambrex Co. (NYSE:CBM) during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 2,131 shares of the biotechnology company’s stock, valued at approximately $100,000.

Other large investors have also added to or reduced their stakes in the company. Marshall Wace LLP acquired a new stake in shares of Cambrex during the 1st quarter worth about $30,000. Hilton Capital Management LLC acquired a new position in shares of Cambrex in the first quarter worth about $94,000. Magnus Financial Group LLC purchased a new position in shares of Cambrex during the 2nd quarter valued at approximately $215,000. Panagora Asset Management Inc. boosted its stake in shares of Cambrex by 205.9% during the 2nd quarter. Panagora Asset Management Inc. now owns 4,894 shares of the biotechnology company’s stock valued at $229,000 after buying an additional 3,294 shares during the last quarter. Finally, Everence Capital Management Inc. acquired a new stake in shares of Cambrex during the second quarter worth approximately $239,000.

NYSE:CBM traded down $0.08 during trading hours on Wednesday, reaching $59.90. 22,057 shares of the stock were exchanged, compared to its average volume of 773,343. The stock has a market capitalization of $2.02 billion, a P/E ratio of 21.62, a P/E/G ratio of 4.68 and a beta of 2.24. The firm has a 50 day simple moving average of $54.75 and a 200-day simple moving average of $45.12. The company has a quick ratio of 1.77, a current ratio of 2.44 and a debt-to-equity ratio of 0.78. Cambrex Co. has a 52 week low of $33.80 and a 52 week high of $69.43.

A number of brokerages recently issued reports on CBM. ValuEngine upgraded shares of Cambrex from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 8th. Zacks Investment Research downgraded shares of Cambrex from a “buy” rating to a “hold” rating in a research note on Wednesday, July 24th. Craig Hallum lowered shares of Cambrex from a “buy” rating to a “hold” rating and set a $60.00 price objective for the company. in a report on Monday, August 12th. Finally, William Blair downgraded shares of Cambrex from an “outperform” rating to a “market perform” rating and set a $60.00 target price for the company. in a research report on Wednesday, August 7th. Five equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has issued a strong buy rating to the company’s stock. Cambrex presently has a consensus rating of “Hold” and a consensus price target of $52.00.

Cambrex Profile

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.

Further Reading: Options Trading

Institutional Ownership by Quarter for Cambrex (NYSE:CBM)

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.